EGFR and neoplasm: Considering one of the main challenges with antibody conjugates is to ensure full antibody functionality, the authors demonstrated preserved EGFR recognition ability of cetuximab after chelation and radiolabeling, as demonstrated by a tumor-to-background noise ratio nearly four times higher than blocking group (111).